Linear antimicrobial peptides with activity against herpes simplex virus 1 and Aichi virus.
Vilas Boas. Liana Costa Pereira LC; de Lima. Lídia Maria Pinto LM; Migliolo. Ludovico L; Mendes. Gabriele Dos Santos GD; de Jesus. Maianne Gonçalves MG; Franco. Octávio Luiz OL; Silva. Paula Andréia PA
Key Findings
- LL‑37 showed 96% inhibition of Aichi virus in vitro with a selectivity index of 3.4
- Pa‑MAP achieved ~90% inhibition of HSV‑1 with a selectivity index of 5
- The remaining eight tested peptides showed no significant antiviral activity
Practical Outcomes
- These results are early‑stage and only demonstrate lab‑based virus blocking, so they don’t translate into a usable supplement or treatment yet. For biohackers, the takeaway is that LL‑37 has antiviral promise, but more research is needed before any dosage or protocol can be recommended.
Summary
The study tested 10 lab-made antimicrobial peptides and found that two of them, LL‑37 (a human peptide) and Pa‑MAP (from a fish), can block viruses in cell experiments – LL‑37 stopped Aichi virus by about 96% and Pa‑MAP stopped herpes simplex virus‑1 by about 90%. The other peptides didn’t work well.
Abstract
Viruses are the major cause of disease and mortality worldwide. Nowadays there are treatments based on antivirals or prophylaxis with vaccines. However, the rising number of reports of viral resistance to current antivirals and the emergence of new types of virus has concerned the scientific community. In this scenario, the search for alternative treatments has led scientists to the discovery of antimicrobial peptides (AMPs) derived from many different sources. Since some of them have shown antiviral activities, here we challenged 10 synthetic peptides from different animal and plant sources against, herpes simplex virus 1 (HSV-1), and Aichi virus. Among them, the highlight was Pa-MAP from the polar fish Pleuronectes americanus, which caused around 90% of inhibition of the HSV with a selectivity index of 5 and a virucidal mechanism of action. Moreover, LL-37 from human neutrophils showed 96% of inhibition against the Aichi virus, showing a selectivity index of 3.4. The other evaluated peptides did not show significant antiviral activity. In conclusion, the present study demonstrated that Pa-MAP seems to be a reliable candidate for a possible alternative drug to treat HSV-1 infections. © 2016 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 108: 1-6, 2017.
Study Information
pubmed
2017
2017-03-01T00:00:00.000Z
10.1002/bip.22871
46
39